Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17125449 | FRATAXIN EXPRESSION CONSTRUCTS | December 2020 | January 2024 | Allow | 37 | 2 | 0 | No | No |
| 17253518 | METHOD OF DIFFERENTIATING PRIMORDIAL GERM CELL INTO PRIMORDIAL FOLLICLE IN VITRO | December 2020 | March 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17118981 | HUMANIZED HEART MUSCLE | December 2020 | February 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17118064 | NON-MEIOTIC ALLELE INTROGRESSION | December 2020 | January 2024 | Abandon | 38 | 1 | 1 | No | No |
| 16952807 | HUMANIZED SKELETAL MUSCLE | November 2020 | May 2024 | Allow | 42 | 2 | 0 | No | No |
| 17091203 | Methods for the Treatment and Diagnosis of Alzheimer's Disease and Traumatic Brain Injuries | November 2020 | August 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17086072 | METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE | October 2020 | June 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 17065541 | Method For Differentiating Pluripotent Stem Cells Into Desired Cell Type | October 2020 | September 2023 | Allow | 36 | 1 | 0 | No | No |
| 17039006 | CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCS | September 2020 | May 2025 | Allow | 56 | 4 | 1 | Yes | No |
| 17040818 | Gene Editing for Autosomal Dominant Diseases | September 2020 | May 2025 | Abandon | 55 | 1 | 1 | No | No |
| 16937370 | MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC | July 2020 | April 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 16925518 | IN VITRO PRODUCTION OF EXPANDED POTENTIAL STEM CELLS | July 2020 | November 2023 | Allow | 40 | 1 | 1 | No | No |
| 16913315 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | June 2020 | May 2023 | Allow | 35 | 1 | 0 | No | No |
| 16913306 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | June 2020 | May 2023 | Allow | 34 | 1 | 0 | No | No |
| 16902368 | METHODS FOR PRODUCING HEPATOCYTES | June 2020 | March 2023 | Allow | 33 | 1 | 0 | No | No |
| 16895732 | EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER | June 2020 | July 2023 | Abandon | 37 | 1 | 0 | No | No |
| 16890697 | PHARMACEUTICAL COMPOSITION COMPRISING AIMP2-DX2 FOR PREVENTING OR TREATING NEURONAL DISEASES AND USE THEREOF | June 2020 | June 2024 | Allow | 49 | 3 | 0 | Yes | No |
| 16869394 | STEM CELL COMPOSITIONS FOR COSMETIC AND DERMATOLOGIC USE | May 2020 | May 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16869232 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | May 2020 | February 2021 | Allow | 10 | 1 | 0 | Yes | No |
| 16857894 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | April 2020 | September 2020 | Allow | 5 | 1 | 0 | No | No |
| 16757811 | COMPOSITIONS AND METHODS USEFUL IN REGENERATIVE MEDICINE | April 2020 | August 2024 | Allow | 52 | 6 | 1 | Yes | No |
| 16811086 | STEM CELL-DERIVED SERTOLI-LIKE CELL, PREPARATION METHOD THEREFOR, AND USE THEREOF | March 2020 | June 2024 | Allow | 51 | 4 | 1 | Yes | No |
| 16808170 | METHOD FOR PREPARATION OF RETINAL GANGLION CELLS | March 2020 | February 2024 | Allow | 48 | 4 | 0 | Yes | No |
| 16800988 | DELIVERY AND USE OF THE CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR HEPATIC TARGETING AND THERAPY | February 2020 | December 2023 | Allow | 45 | 2 | 0 | No | No |
| 16787980 | RECOMBINANT ADENO-ASSOCIATED VECTORS FOR TARGETED TREATMENT | February 2020 | July 2023 | Allow | 41 | 1 | 1 | Yes | No |
| 16638440 | METHOD FOR DEVELOPING ORGAN THAT LACKS SPECIFIC FUNCTIONAL CELL | February 2020 | July 2021 | Allow | 17 | 2 | 0 | Yes | No |
| 16776765 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | January 2020 | April 2020 | Allow | 2 | 1 | 0 | No | No |
| 16752535 | METHODS FOR REPROGRAMMING CELLS AND USES THEREOF | January 2020 | June 2023 | Allow | 41 | 1 | 0 | No | No |
| 16752462 | METHODS FOR REPROGRAMMING CELLS AND USES THEREOF | January 2020 | May 2023 | Abandon | 40 | 1 | 0 | No | No |
| 16747406 | METHODS FOR USE OF SEX SORTED SEMEN TO IMPROVE GENETIC MANAGEMENT IN SWINE | January 2020 | June 2024 | Allow | 53 | 4 | 0 | No | No |
| 16737768 | METHODS FOR MAKING AND USING SINOATRIAL NODE-LIKE PACEMAKER CARDIOMYOCYTES AND VENTRICULAR-LIKE CARDIOMYOCYTES | January 2020 | March 2023 | Allow | 39 | 1 | 0 | No | No |
| 16734892 | THIENOPYRIMIDINES AND USES THEREOF | January 2020 | April 2023 | Abandon | 39 | 0 | 1 | No | No |
| 16626052 | IMMORTALIZED SWEAT GLAND MYOEPITHELIAL CELL | December 2019 | May 2021 | Allow | 17 | 1 | 1 | Yes | No |
| 16715597 | METHODS FOR COLLECTING AND USING PLACENTA CORD BLOOD STEM CELLS | December 2019 | December 2023 | Abandon | 48 | 2 | 0 | No | No |
| 16708007 | METHODS FOR INCREASING GENETIC PROGRESS IN A LINE OR BREED OF SWINE USING SEX-SELECTED SPERM CELLS | December 2019 | January 2023 | Allow | 37 | 1 | 0 | No | No |
| 16702275 | RECOMBINANT NK CELLS EXPRESSING CO-STIMULATORY MOLECULES | December 2019 | March 2023 | Allow | 40 | 1 | 1 | Yes | No |
| 16617241 | A THERAPY FOR POLYGLUTAMINE (POLYQ) DISEASES | November 2019 | August 2022 | Allow | 32 | 3 | 0 | Yes | No |
| 16614541 | METHODS OF INHIBITING AGING AND TREATING AGING-RELATED DISORDERS | November 2019 | March 2024 | Abandon | 52 | 3 | 1 | No | No |
| 16669094 | METHODS FOR ALTERING GENE EXPRESSION FOR GENETIC DISORDERS | October 2019 | June 2024 | Abandon | 55 | 3 | 1 | No | No |
| 16665821 | METHODS FOR REPROGRAMMING SOMATIC CELLS | October 2019 | January 2024 | Allow | 50 | 2 | 1 | No | No |
| 16609110 | GENETICALLY ENGINEERED NON-HUMAN MAMMAL, CONSTRUCTION METHOD THEREFOR AND USE THEREOF | October 2019 | September 2023 | Allow | 47 | 2 | 1 | Yes | No |
| 16659214 | LIVER-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF | October 2019 | January 2023 | Allow | 38 | 1 | 1 | No | No |
| 16656484 | GENOMIC ENGINEERING OF PLURIPOTENT CELLS | October 2019 | December 2021 | Allow | 26 | 3 | 1 | Yes | No |
| 16605489 | METHODS AND COMPOSITIONS FOR TREATING SKELETAL MUSCULAR DYSTROPHY | October 2019 | February 2023 | Allow | 40 | 1 | 1 | Yes | No |
| 16576411 | ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF | September 2019 | November 2020 | Allow | 14 | 1 | 1 | Yes | No |
| 16495677 | METHOD OF DETECTING POLYCOMB REPRESSIVE COMPLEX ACTIVITY | September 2019 | March 2024 | Allow | 54 | 2 | 1 | Yes | No |
| 16567059 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | September 2019 | June 2022 | Allow | 33 | 1 | 0 | No | No |
| 16567682 | NON-MEIOTIC ALLELE INTROGRESSION | September 2019 | November 2020 | Allow | 14 | 1 | 1 | Yes | No |
| 16567655 | NON-MEIOTIC ALLELE INTROGRESSION | September 2019 | September 2020 | Allow | 12 | 2 | 1 | Yes | No |
| 16562497 | METHODS AND PRODUCTS FOR TRANSFECTION | September 2019 | June 2022 | Allow | 34 | 1 | 0 | No | No |
| 16554792 | DECELLULARIZATION AND RECELLULARIZATION OF ORGANS AND TISSUES | August 2019 | September 2022 | Abandon | 37 | 4 | 2 | Yes | No |
| 16550475 | METHOD FOR THE TREATMENT OF MALIGNANCIES | August 2019 | September 2022 | Allow | 37 | 1 | 0 | No | No |
| 16541516 | CAPSID | August 2019 | July 2024 | Allow | 59 | 4 | 2 | Yes | No |
| 16527629 | CARDIAC MYOFIBRIL INDUCTION | July 2019 | August 2022 | Abandon | 36 | 0 | 1 | No | No |
| 16526327 | ADENO-ASSOCIATED VIRUS VECTORS ENCODING MODIFIED G6PC AND USES THEREOF | July 2019 | August 2022 | Allow | 37 | 1 | 1 | No | No |
| 16523567 | AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE | July 2019 | May 2023 | Allow | 45 | 2 | 1 | No | No |
| 16519179 | Prevention and treatment of bone and cartilage damage or disease | July 2019 | September 2022 | Allow | 38 | 2 | 1 | Yes | No |
| 16460160 | DETARGETED ADENOVIRUS VARIANTS AND RELATED METHODS | July 2019 | March 2022 | Allow | 32 | 1 | 0 | Yes | No |
| 16454168 | MEDIA FOR CULTURING STEM CELLS | June 2019 | August 2022 | Allow | 37 | 1 | 1 | No | No |
| 16452376 | PLURIPOTENT STEM CELL THAT INDUCES REPAIR AND REGENERATION AFTER MYOCARDIAL INFARCTION | June 2019 | January 2020 | Allow | 7 | 1 | 0 | No | No |
| 16449438 | MICROFLUIDIC DEVICE, SYSTEM AND METHODS THEREOF FOR MEASURING AND RECORDING ELECTRICAL SIGNALS FROM A POOL OF MULTIPLE NEMATODES | June 2019 | May 2022 | Allow | 35 | 0 | 1 | Yes | No |
| 16443418 | BOS TAURUS VARIETY 'JE840003146074527' AND METHODS OF USE THEROF | June 2019 | February 2021 | Allow | 20 | 3 | 1 | Yes | No |
| 16435441 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD28 | June 2019 | December 2021 | Allow | 30 | 4 | 1 | No | No |
| 16430251 | GENETICALLY STERILE ANIMALS | June 2019 | November 2022 | Abandon | 42 | 2 | 1 | No | No |
| 16428763 | TRANSGENIC ANIMAL FOR PRODUCTION OF ANTIBODIES HAVING MINIMAL CDRS | May 2019 | February 2020 | Allow | 8 | 1 | 0 | Yes | No |
| 16426081 | Methods for monitoring physiological status of a body organ | May 2019 | August 2022 | Allow | 39 | 1 | 1 | No | No |
| 16424356 | NON-MEIOTIC ALLELE INTROGRESSION | May 2019 | September 2020 | Allow | 16 | 2 | 1 | Yes | No |
| 16424201 | MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC | May 2019 | May 2020 | Allow | 12 | 1 | 1 | Yes | No |
| 16409656 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TIM-3 | May 2019 | September 2021 | Allow | 28 | 3 | 1 | Yes | No |
| 16402175 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | May 2019 | September 2019 | Allow | 4 | 1 | 0 | No | No |
| 16379668 | GENOMIC ENGINEERING OF PLURIPOTENT CELLS | April 2019 | September 2020 | Allow | 17 | 2 | 1 | Yes | No |
| 16374482 | METHODS AND PRODUCTS FOR TRANSFECTION | April 2019 | August 2019 | Allow | 5 | 1 | 0 | No | No |
| 16365306 | BOS TAURUS Variety 'HO840003150607238' and Methods of Use Thereof | March 2019 | February 2021 | Allow | 23 | 3 | 2 | Yes | No |
| 16294619 | EFFICIENT NON-MEIOTIC ALLELE INTROGRESSION IN LIVESTOCK | March 2019 | November 2021 | Abandon | 33 | 4 | 0 | Yes | No |
| 16284443 | FLOWABLE BIRTH TISSUE COMPOSITION AND RELATED METHODS | February 2019 | February 2021 | Allow | 23 | 2 | 1 | No | No |
| 16281490 | METHODS OF GENERATING GLIAL AND NEURONAL CELLS AND USE OF SAME FOR THE TREATMENT OF MEDICAL CONDITIONS OF THE CNS | February 2019 | June 2022 | Allow | 40 | 1 | 1 | No | No |
| 16077682 | CULTURE MEDIUM FOR USE IN DIFFERENTIATION OF PLURIPOTENT STEM CELL INTO NEURAL STEM CELL, AND USE THEREOF | January 2019 | June 2021 | Abandon | 34 | 2 | 0 | No | No |
| 16248569 | METHODS FOR INCREASING GENETIC PROGRESS IN A LINE OR BREED OF SWINE USING SEX-SELECTED SPERM CELLS | January 2019 | September 2019 | Allow | 8 | 1 | 0 | No | No |
| 16245435 | DECELLULARIZATION AND RECELLULARIZATION OF SOLID ORGANS | January 2019 | September 2023 | Abandon | 56 | 2 | 1 | No | No |
| 16239315 | METHODS FOR USE OF SEX SORTED SEMEN TO IMPROVE GENETIC MANAGEMENT IN SWINE | January 2019 | September 2019 | Allow | 8 | 1 | 0 | No | No |
| 16082926 | CELL REPROGRAMMING METHOD USING PHYSICAL STIMULATION-MEDIATED ENVIRONMENTAL INFLUX | December 2018 | October 2023 | Allow | 60 | 5 | 1 | Yes | No |
| 16216903 | GENERATION AND MAINTENANCE OF STEM CELLS | December 2018 | March 2024 | Allow | 60 | 4 | 0 | Yes | No |
| 16209807 | TRANSGENIC ANIMAL FOR PRODUCTION OF ANTIBODIES HAVING MINIMAL CDRS | December 2018 | May 2019 | Allow | 5 | 1 | 0 | No | No |
| 16206816 | EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER | November 2018 | January 2020 | Allow | 14 | 1 | 0 | Yes | No |
| 16204320 | ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS | November 2018 | August 2022 | Allow | 45 | 1 | 1 | Yes | No |
| 16201392 | Hybrid Dairy Cattle and Systems for Maximizing Hybrid Advantage | November 2018 | November 2022 | Abandon | 47 | 1 | 1 | Yes | No |
| 16200974 | Methods And Compositions For Regulating Gene Expression | November 2018 | August 2022 | Allow | 44 | 1 | 0 | No | No |
| 16199715 | NON-TOXIC HSV VECTORS FOR EFFICIENT GENE DELIVERY APPLICATIONS AND COMPLEMENTING CELLS FOR THEIR PRODUCTION | November 2018 | September 2024 | Abandon | 60 | 5 | 0 | Yes | No |
| 16195005 | METHODS FOR REPROGRAMMING CELLS AND USES THEREOF | November 2018 | September 2019 | Allow | 10 | 1 | 0 | No | No |
| 16189658 | Hybrid Dairy Cattle and Systems for Maximizing Hybrid Advantage | November 2018 | December 2021 | Allow | 37 | 0 | 0 | No | No |
| 16189603 | Hybrid Dairy Cattle and Systems for Maximizing Hybrid Advantage | November 2018 | April 2022 | Allow | 41 | 1 | 0 | No | No |
| 16184466 | AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE | November 2018 | April 2019 | Allow | 5 | 1 | 0 | Yes | No |
| 16183144 | NON-HUMAN ANIMALS HAVING A MUTANT KYNURENINASE GENE | November 2018 | April 2022 | Abandon | 41 | 1 | 0 | No | No |
| 16180835 | METHOD OF PREPARING INJECTION SOLUTION | November 2018 | July 2023 | Abandon | 56 | 2 | 1 | No | No |
| 16180666 | Methods for monitoring physiological status of a body organ | November 2018 | May 2019 | Allow | 6 | 1 | 0 | No | No |
| 16175141 | LIVER-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF | October 2018 | June 2019 | Allow | 8 | 1 | 0 | No | No |
| 16165324 | TRANSFERRIN RECEPTOR TRANSGENIC MODELS | October 2018 | September 2022 | Allow | 47 | 2 | 0 | No | No |
| 16163334 | MURINE-MHC-DEFICIENT HLA-TRANSGENIC NOD-MOUSE MODELS FOR T1D THERAPY DEVELOPMENT | October 2018 | February 2023 | Allow | 52 | 3 | 1 | No | No |
| 16094006 | METHODS AND COMPOSITIONS TO ENHANCE THE ANTI-INFLAMMATORY EFFECTS OF INTERLEUKIN 10 | October 2018 | June 2024 | Abandon | 60 | 6 | 1 | Yes | No |
| 16159375 | REJUVENATED AGED HEMATOPOIETIC STEM CELLS AND METHODS OF USE | October 2018 | February 2024 | Allow | 60 | 5 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NOBLE, MARCIA STEPHENS.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner NOBLE, MARCIA STEPHENS works in Art Unit 1632 and has examined 870 patent applications in our dataset. With an allowance rate of 60.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner NOBLE, MARCIA STEPHENS's allowance rate of 60.9% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by NOBLE, MARCIA STEPHENS receive 2.23 office actions before reaching final disposition. This places the examiner in the 58% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by NOBLE, MARCIA STEPHENS is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +48.9% benefit to allowance rate for applications examined by NOBLE, MARCIA STEPHENS. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.5% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 42.9% of cases where such amendments are filed. This entry rate is in the 66% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 43% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 90.5% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 84.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 70.0% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 5.4% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.